

# CEE UPDATES April 2024




### RECOGNITION OF SINGAPORE'S PATIENT ENGAGEMENT EFFORTS IN THE ASIA-PACIFIC REGION

#### 1<sup>st</sup> International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Student Network Asia-Pacific Region Conference (ISPAC), 16 to 17 February 2024

ACE's patient involvement efforts in Singapore were recognised at ISPAC in February, where thought leaders across the Asia Pacific met virtually to share their insights on patient engagement in healthcare.

ACE is proud to have been awarded **runner up** for the poster presentation on "**Helping Patients Become Equal Stakeholders in Healthcare Decision-Making: The Challenges and Successes of Patient Involvement in Singapore**"

Click on the image to view the winning entry.



### **CONNECTING WITH LOCAL PATIENT ORGANISATIONS**

#### Singapore Cancer Society Members' Townhall Day, 23 February 2024





The CEE team was invited to share ACE's patient involvement initiatives and upcoming HTA training opportunities with members of Singapore Cancer Society (SCS).

The team showcased the collaborative efforts between ACE and SCS, and was delighted to be able to interact with SCS staff and members to build meaningful connections.


### HTA LEARNING MODULE FOR PATIENTS AND CARERS

Following feedback from the health technology assessment (HTA) training workshops in 2023, the CEE team is developing a series of bite-sized learning modules about different aspects of HTA to facilitate self-directed learning by patients and the public.

NEW

The content of the modules will focus on providing answers to common questions on HTA and ACE's work in plain language.

The first piece in this series is titled "*How do patients contribute to ACE's work?*" This module describes the different opportunities for patients and carers to contribute to ACE's work, including:



Stay tuned for our next learning module on "What is HTA?" You can also send any suggestions on the learning modules to <u>ACE\_CEE@moh.gov.sg</u>.

LEARNING

MODULE FOR PATIENTS AND THE PUBLIC:

### **PATIENT INPUT**

#### **48** PATIENT RESPONSES ABOUT ACE'S DRUG EVALUATIONS WERE GATHERED FOR

#### 6 TOPICS PRESENTED TO THE DRUG ADVISORY COMMITTEE IN MARCH 2024

Patients and carers were invited to provide their lived experiences about medical conditions, treatments and unmet needs to inform ACE's technical evaluations. The insights received were very helpful to inform the Drug Advisory Committee's (DAC) funding recommendations.

The CEE team notifies patient organisations of the DAC's funding recommendations after each meeting and provides feedback on which information provided by patients was most helpful to inform the DAC's deliberations. The CEE team also invites suggestions on how the patient involvement processes can improve.

### PATIENT FACTSHEETS

#### **3** PATIENT FACTSHEETS PUBLISHED SINCE JANUARY 2024

FIND OUT MORE


Patient factsheets are co-developed with patient organisations and clinicians to equip patients with helpful and evidence-based information about different medical conditions and encourage shared decision-making with their doctors about their healthcare needs.

Links to relevant patient organisations are also included in the factsheets for interested readers to seek more information on peer support.

#### New factsheets:

- Injectable treatments for retinal diseases
- Oral and injectable drugs for atopic eczema
- Treatments for advanced renal cell carcinoma (updated)

We would like to thank members from the patient organisations for providing feedback and suggestions to help inform the content and layout of these new factsheets.





### **PLAIN ENGLISH SUMMARIES**



#### **5** NEW PLAIN ENGLISH SUMMARIES PUBLISHED SINCE JANUARY 2024



Plain English summaries (PES) provide brief information about the treatments and conditions that have been evaluated by ACE and describe the key funding recommendations made by the Drug Advisory Committee.

#### **Newly published PES:**

- Aflibercept and faricimab for treating diabetic macular oedema and age-related macular degeneration
- Pembrolizumab for treating advanced cervical cancer
- Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
- Pembrolizumab for treating renal cell carcinoma after kidney surgery
- Tafamidis for treating transthyretin amyloid cardiomyopathy
- Treatments for moderate to severe eczema that has not improved with previous treatment
- Olaparib for BRCA-mutated HER2-negative early breast cancer (updated)
- Regorafenib and sunitinib for advanced gastrointestinal stromal tumours (updated)
- Sodium-glucose co-transporter 2 inhibitors for treating heart failure and chronic kidney disease (updated)
- Treatments for advanced neuroendocrine tumours (updated)
- Treatments for advanced ovarian cancer (updated)
- Treatments for advanced renal cell carcinoma (updated)
- Treatments for advanced urothelial cancer (updated)
- Treatments for chronic lymphocytic leukaemia (updated)
- Treatments for mantle cell lymphoma (updated)

### **UPCOMING EVENT**



VALUE-BASED HEALTHCARE CONFERENCE 2024 22-23 AUGUST 2024

### Breakout session for patients and carers 23 August 2024 (afternoon) Sands Expo & Convention Centre, Marina Bay Sands

### This half-day session titled "Co-creating Meaningful Patient Engagement in

*Healthcare*" aims to encourage patient engagement in healthcare decision-making in Singapore.

Hear from a diverse group of local and international patient leaders as they share their contributions as partners in healthcare, and their journey from being a patient or carer to an active patient advocate.



Limited slots available. Scan or click on the QR code to express your interest to attend this session.



## Breakout session for patients and carers 23 August 2024

Panel discussion 1: Patients are essential partners in healthcare decision-making - a call to action



**Ms Ai Ling Sim-Devadas** Lee Kong Chian School of Medicine; SingHealth Patient Advocacy Network



**Dr Laurie J. Goldsmith** National University of Singapore; Simon Fraser University, Canada



**Dr Susannah Morris** University of Melbourne

Panel discussion 2: Transforming patient engagement in Singapore – my journey from patient/carer to patient advocate



#### About CEE

The Consumer Engagement and Education (CEE) team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors.

Tell us what matters to you, your organisation or your community. Email us at <u>ACE\_CEE@moh.gov.sg</u>.



The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education. © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore. Published on 30 April 2024. To find out more about ACE, scan the QR code or visit <u>www.ace-hta.gov.sg</u>. You can also follow us on social media at: